IMPACT OF ANTIFIBROTIC USE ON HEALTHCARE RESOURCE USE AND COST IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) IN A COMMERCIALLY INSURED PATIENT POPULATION